Back to All Events

A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma.

Khaled H, Azim HA, Barsoum E, Chahine G, Shamseddine A, Metaal GA, Omar A, Jazeih AR, Haggag R, Badran A.

Mol Clin Oncol. 2015 Sep;3(5):1099-1102.